Life Sciences Archive » October, 2009

Life Sciences - October, 2009

197 articles

• FDA Says P&G Is Illegally Marketing Vicks Products
• US Probes Shire's Marketing For Adderall, Others
• With Divestitures, FTC Allows Merck-Schering Deal
• Express Scripts Prevails In Another AWP Fight
• Sanofi-Aventis Sues Sandoz Over Taxotere Drug Patent
• Abbott Sues Impax Over Generic TriCor ANDA
• Sequenom Misrepresented Medical Advancements: Suit
• House Dems Tout New Health Care Reform Bill
• 7th Circ. Affirms Toss Of Schering-Plough Branding Suit
• AstraZeneca To Pay $520M In Seroquel Off-Label Case
• Ex-DHB Head Loses Bid To Toss Fraud Charges
• Genzyme Fights Dismissal Of D&O Policy Suit
• Pfizer Returns To Fray In Pharma Group's Wyeth Suit
• Mayo Asks High Court To Hear Test Patents Fight
• Pitt Sends Radiation Patent Suit Back To Fed. Circ.
• CORRECTED: Warner Chilcott Birth Control IP Suit To Be Heard In Del.
• Pfizer Sanctioned In BYU's Suit Over NSAID Drugs
• 9th Circ. Says Wash. Plan B Sale Rules Still Stand
• Stryker, Execs Indicted For Bone Device Sales Fraud
• 9th Circ. Revives Matrixx Zicam Shareholder Action
• GOP Bill Aims To Keep Convicts Away From Drug Trials
• Wyeth, Amgen Face Patent Suit Over Enbrel
• Qualitest Expands Recall To 250M Syringes
• Watson Settles with Barr Over Oxytrol
• Barring Pay-For-Delay, Reverse Payment Settlements
• FTC Accuses Boehringer Of Subpoena Delay Tactics
• Vascular Solutions Targets Rival Over Employee Jump
• 10th Circ. Finds TMJ Implant Maker Liable For Penalties
• Biolitec Sued By Distributor For Costs In Patent Suits
• FDA Warns Sanofi Over 'Misleading' Uroxatral Ads
• FDA Affirms Exclusivity Period For Shire ADHD Drug
• Roche Wins Reversal Of $7M Accutane Verdict
• Shareholder E-Forums Could Alter Proxy Landscape
• Blank Rome Snags Corp. Finance Attorney Greenfield
• Patent Cliff Has Drug Companies On Deal Hunt: Report
• Purdue Settles OxyContin Patent Spat With Apotex
• Judge Cans NutriSystem Derivative Action
• Sens. Back Long-Term Protections For Biologic Drugs
• Obama Administration Backs Revival Of Vioxx Case
• Medical Supplier Settles J&J OneTouch Counterfeit Suit
• Wyeth Hit With Punitive Damages In Prempro Case
• Roche Appeals Ranbaxy Noninfringement Ruling
• Insurers Hit Over Denying Cancer Patients Coverage
• Wyeth, Cordis Ask To Boot Boston Scientific Stent Case
• Minn. Court Says Medtronic Plaintiffs' Claims Preempted
• Alcon Sues Apotex Over Glaucoma Eye Drop ANDA
• FDA Unwilling To Change View On Dangers Of Zicam
• Court Sees Infringement Of Allergan Glaucoma Patent
• Video Testimony Proper In AndroGel Probe: DC Circ.
• GAO Says FDA Slow To Debar Convicted Investigators
• Eli Lilly To Pay $45M To SC In Zyprexa Off-Label Deal
• Novartis Loses First Zometa Trial, Must Pay $3.2M
• EU Blesses Merck's $41B Schering-Plough Deal
• The Patentability Of 'Personalized Medicine' Claims
• India, Brazil Prepare WTO Action Over EU Drug Seizures
• Decertification Stands In Canada Vioxx Suit
• Lessons From Reed V. Advocate Health Care
• Trimeris Shareholder Tries To Halt $81M Arigene Deal
• 6th Circ. Puts Omnicare Securities Suit On Life Support
• Novartis Standing In Patent Suit V. Teva Still Unclear
• Bausch Asks Judge To Toss Most Of ReNu MDL Suits
• Blueprint For Evaluating And Mitigating Drug Risk
• Novartis Fails To Nix Pay Claims In Sex Bias Action
• Guidant Investors Lose Bid To Revive Class Action
• Baxter Mislabeled Chemotherapy Device: FDA
• China — Home And Away: The Next IP Powerhouse
• Cedars-Sinai Patient Sues For Radiation Overexposure
• Freedom Medical Hits Rivals With Antitrust Suit
• Teva Found To Infringe Alcon Vigamox Patent
• Wyeth Hits Rivals With New Patent For Piglet Vaccine
• FDA Warns Philips Healthcare Of Quality Control Issues
• Tafas Fights Bid To Nix Ruling On USPTO Rules
• Gen-Probe Hits Becton Dickinson With Test Patent Suit
• Ex-Foley, AstraZeneca Lawyers Launch IP Boutique
• Roche Sues Credit Suisse Over $545M ARS
• Mutual Loses Bid For Injunction In Colchicine Suit
• FDA Eyes Fire Issues With Abbott, Hospira Devices
• Mylan, Others To Pay $124M Over Medicaid Rebates
• Generics Failure-To-Warn Case Enters Oral Arguments
• Jury Awards Infosint $15M In Lexapro Patent Fight
• 2nd Circ. Gives New Life To DDAVP Antitrust Case
• IP Law Group Gives Fed. Circ. Input In Ariad Case
• GE To Pay SonoSite $21M, Royalties Over Ultrasound IP
• HIG Capital To Acquire Allion For $278M
• Teva Sues Mylan, Natco Over Copaxone ANDA
• Patent-Eligibility In The Life Sciences
• Q&A With LeClairRyan's Stanley North
• Rite Aid To Sell $250M Notes To Refinance Debt
• Pfizer Hit With $1.3B Fine For Bextra Marketing
• NY Judge Halts Mandatory Swine Flu Shots
• Sens. Balk At Patent Reform Act Review Provisions
• Novo Nordisk Sues Ex-Employee Who Moved To Sandoz
• Ala. High Court Reverses $275M AWP Decisions
• Philip Morris Drops Fight Over SF Tobacco Sales Ban
• Suit Over Allegan Breast Implant Ruled Preempted
• Sun Retreats From Alzheimer Drug Battle
• Pharma Group Renews Bid To Halt Pfizer-Wyeth Deal
• Lundbeck Price-Gouging Claims Survive Bid To Toss
• Public-Deal Makers Take Page From Private Equity Book
• Covidien's Purchase Of Aspect Spurs Shareholder Suit
• Schlichter Hits Back In Yaz MDL Counsel Fray
• Kentucky AG Fights To Remand OxyContin Claims
• Skandia Joins Race For Lead Status In Pfizer Case
• DOL Backs Novartis Sales Reps In FLSA Suit Appeal
• Bill Aims To Eliminate Generic-Drug Labeling Delays
• CIBA Seeks Acuvue Ban In Lens Patent Spat With J&J
• ARRA Impacts On Health Care
• KV Slaps Uriach With Trade Secrets, Contract Suit
• Q&A With Arnold & Porter's Robert Weiner
• Pfizer Gets FTC Blessing To Buy Wyeth
• Top Fed. Circ. Rulings That Came Down Last Quarter
• 6th Time's A Charm For Gilead Securities Action
• Walgreen Sued Over Reneging On $1.4M Buyout Offer
• Crisis Sparks New Focus On Reverse Breakup Fees
• $110M E-Ferol Settlement Gets Tentative Court OK
• Pfizer Settles With Mylan Units Over Generic Vfend
• Thermal Scalpel Sews Up Cutting Tool Patent Spat
• Stiefel Calls Out Perrigo For Generic Rogaine Plan
• Eli Lilly Reaches $13M Zyprexa Settlement With Idaho
• Talecris Biotherapeutics Offers $550M In Senior Notes
• Shire Settles Generic Adderall Spat With Sandoz
• Pharma Group Tries To Halt Pfizer-Wyeth Deal
• Philadelphia Jury Slaps GSK With $2.5M Paxil Verdict
• AmMed Wants Liberty Sanctioned In Marketing Spat
• Yaz MDL Plaintiffs Balk At Schlicter Interim Counsel Bid
• Defending Patent Infringement With 'Ensnarement'
• Plant Biotech Co. Phyton Buys Chemotherapy Patents
• Dentsply To Challenge $44M Verdict In Contract Case
• Teva Hits Back In Gilead Patent Suit Over HIV Drug
• Onyx Adds Cancer Drug Maker Proteolix For $276M
• Court Not 'Neutral' On RyMed Trademark Claims
• Health Workers Seek To Stop Mandatory Swine Flu Shot
• Funds Try To Revive Sanofi Obesity Drug Securities Suit
• Stryker Wins $14M Judgment Against Insurer
• Kimberly-Clark To Buy I-Flow With $324M Cash Offer
• Teva Sued Over Plans For Generic Angiomax
• 1st Circ. Considers Rejecting $24M Zoladex Deal
• Rite Aid Moves To Dismiss 'Redundant' OT Suit
• Class Action Over Cephalon Off-Label Claims Tossed
• Investors Compete To Lead Pfizer Derivative Suit
• Endologix Hit With Patent Suit Over Stent Grafts
• USPTO Drops Controversial Rules Package
• Fen-Phen Attorneys' Fees Of $567M Justified: 3rd Circ.
• Teva Slaps Lupin With Patent Suit Over Seasonale
• GSK Sues Over Genentech Antibody Patent
• FDA's Trazodone Facility Worries Fixed: Labopharm
• US Tries To Quash Depositions In Drug Price MDL
• Unomedical Pulls Potentially Lethal Resuscitators
• Pfizer, Wyeth Drugs Put On FDA Watch List
• Electrochem Hit With $21.7M Verdict In Secrets Case
• Fed. Circ. To Weigh In On Written Description Rule
• Impax Agrees to Settle Flomax Patent Dispute
• GE, SonoSite Seek To Smooth Over Ultrasound Suit
• Sandoz's Plan For Generic Caduet Infringes: Pfizer
• Eli Lilly Settles $6B Zyprexa Suit With State Of SC
• FDA Orders Post-Market Review Of Spinal Screws
• Thermal Scalpel Cuts Tyco, Covidien From IP Suit
• Effects Of Biosimilars Legislation On Patent Litigation
• Sanofi-Sun Settlement In Eloxatin Suit Ruled Valid
• Patent, Antitrust Case Over Generic Amrix Bifurcated
• Bayer's Yaz Ads Violated Racketeering Law: Suit
• Iqbal Ruling Impact Starting To Be Felt
• Biopure Exec Gets 3 Years For Fake Cancer Defense
• Court Denies Preemption Plea In Generic-Drug Case
• Genzyme Sues Endo In Latest Renagel ANDA Suit
• Sidley Austin Adds FDA Regulatory Counsel
• EU Court Revives Glaxo Dual Pricing Case
• Novartis Plaintiffs Look To 6th Circ. For Help
• Allou Investors Lose Bid For Cert. In KPMG Suit
• EU Targets Sanofi, Other Drug Cos. In Antitrust Raids
• Medtronic Seeks Dismissal Of InFuse Securities Case
• Astra Ex-CEO Must Pay Back $7M: Mass. High Court
• High Court Rejects Mylan Appeal Of Takeda Atty Fees
• Bristol-Myers, Sanofi Abused Plavix Patent: Apotex
• Patent Suit Ends After Lupin Acquires Antara Rights
• High Court Needs To Fatten Its Docket: Attys
• FDA Deviations In Menaflex Knee Device Clearance
• 2 Juries To Hear Last Cordis, Boston Sci Stent Claims
• Bra-Maker Seeks Boost From Supreme Court
• Genentech Wants Firm Kicked Off Sanofi Patent Case
• Affymax Files $100M Mixed Securities Shelf
• Biotech Co. Celldex Completes $90M Curagen Buy
• Botox Maker Sues FDA Over Off-Label Marketing Ban
• Bayer Sued Over Men's One-A-Day Selenium Claims
• FTC Acquisition Challenges In Health Care
• Penumbra Recalls Another Make Of Catheter
• Roche Valcyte Patent Ruled Valid, But Not Infringed
• Pfizer Gets Lipitor Fraudulent Marketing Suit Tossed
• FDA Unveils Risk Strategies For Drug Industry
• Securities Suit Against Par Pharma Execs To Go On
• Q&A With Perkins Coie's Dan Bagatell
• Pozen Scores Win In Shareholder Suit Over Treximet
• Novo Challenges Order To Trim Prandin Patent
• Gatekeeper's New Tool: Heightened Pleading Standards
• Sanofi-Aventis To Acquire Fovea For €370M
• FDA Revises Plans On Drug Risk Communications
• Hospital To Appeal In CR Bard Catheter Antitrust Suit